Search results
Results from the WOW.Com Content Network
The Medicaid Drug Rebate Program provides for mandatory rebates on innovator drugs (e.g., brand drugs), blood clotting factors, drugs Food and Drug Administration-approved exclusively for pediatric indications, and non-innovator drugs (e.g., generic drugs). [1] The maximum rebate is capped at 100% of the Average Manufacturer Price (AMP).
The Centers for Medicare & Medicaid Services estimated that coverage under the Biden proposal would cost about $40 billion over 10 years, including an extra $3.8 billion for states.
Centers for Medicare & Medicaid officials estimated the anti-obesity drugs would cost Medicare and Medicaid about $40 billion over a decade. States would be expected to pay for about $3.8 billion ...
Medicaid beneficiaries in North Carolina will soon be able to get GLP-1 drugs like Wegovy, Saxenda and Zepbound covered. NC Medicaid to cover weight-loss drugs like Wegovy, after access cut for ...
Objective: To describe state Medicaid agencies' policies and oversight activities related to drugs purchased under 340B. [44] Findings: (1) Approximately half of states have written 340B policies that direct covered entities to bill Medicaid at cost for 340B-purchased drugs. (2) States do not have necessary pricing information to create prepay ...
Only 38% of drugs approved in the 1990s and 19% of the drugs approved since 2000 were on the formulary. [citation needed] In 2012, the plan required Medicare beneficiaries whose total drug costs reach $2,930 to pay 100% of prescription costs until $4,700 is spent out of pocket.
"These selected drugs accounted for about $41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14%, during that time period," Biden administration officials ...
In December 2016, a New Drug Application was filed with the US Food and Drug Administration (FDA), and in October 2017, a FDA advisory committee approved it unanimously. [65] In December 2017, the injectable version with the brand name Ozempic was approved for use by people with diabetes in the United States, [30] [66] and, in January 2018, in ...